Equipment and Processing Report
PharmTech's monthly newsletter, Equipment & Processing Report, reviews the Editor's Picks for the September 2008 edition from LiquaJet and Yokogawa.
LiquaJet
Technology mills resistant materials
LiquaJet (Moorestown, NJ), a new company created by the Jet Pulverizer Company (Moorestown), offers jet-milling services based on a new, proprietary technology. The technology uses high-purity compressed liquid nitrogen rather than compressed gas. The compressed liquid nitrogen expands after entering the jet-milling chamber and provides greater pressure and force than compressed gas does.
The process mills materials that were previously ungrindable. For example, the technology grinds plastic and polymers that could previously be reduced to 100–200 µm to less than 30 µm, according to the company.
The LiquaJet technology contains no moving parts, prevents contamination, and does not create additional heat. The technology minimizes material loss and produces high yields that comply with good manufacturing practices. The company is inspected by the US Food and Drug Administration.
Yokogawa Corporation of America
Production-control system has new features
Yokogawa Corporation of America (Newnan, GA) has added pharmaceutical batch-control capabilities to its “Centum VP” integrated production-control system. New features include recipe-management and process-management functions in addition to the application’s unit-supervision and process-control tools.
The Centum VP software now provides a configurable unit faceplate that lets users monitor and execute batches through an interface. The application also features standard displays for product overview, product control, and unit control for recipe and product selection. The displays offer automatic, current documentation of the batch logic.
In addition, the software separates recipe data from equipment data and provides unit-based exception handling. The latter function allows batch engineers to create modular procedures for main production activities, engineer exception handling through unit monitors, and interrupt processing if necessary. Thus, automation engineers can execute failure-handling logic one time, rather than during each phase of production.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.